Navigation Links
MedImmune to Present 11 Abstracts on Influenza at 45th Annual National Immunization Conference
Date:3/29/2011

WASHINGTON, March 29, 2011 /PRNewswire/ -- MedImmune announced today it will present a total of 11 abstracts at the 45th National Immunization Conference (NIC) at the Washington Hilton in Washington, DC, March 28 - 31, 2011.  These abstracts advance the body of existing data and knowledge surrounding influenza prevention and trends in vaccination, highlighting MedImmune's strong leadership in patient health in various medical settings.

"MedImmune is pleased to announce new research on school-located influenza vaccination programs and use of influenza vaccines in special populations," said William Martone, MD, senior vice president of medical and scientific affairs at MedImmune. "We believe the data being presented at NIC will help the medical community explore innovative ways to prevent influenza in and outside of the medical home."

MedImmune abstracts to be presented at NIC on school-located influenza vaccination programs include:

  • Factors Associated with Increased Vaccination In 2009 H1N1 School-Located Influenza Vaccination Programs. Ambrose CS, et al. Poster Session: March 29, 2011 Time: 10 - 11 AM, 3 - 4 PM; Columbia Hall, Poster # 25171
  • The Impact of School-Located Influenza Vaccination Programs on Student Absenteeism: A Review of the US Literature. Hull, HF, et al. Poster Session: March 29, 2011 Time: 10 - 11 AM, 3 - 4 PM; Columbia Hall, Poster # 25129
  • Current Experience with School-Located Influenza Vaccination Programs in the United States:  A Review of the Medical Literature. Hull, HF, et al. Poster Session: March 29, 2011 Time: 10 - 11 AM, 3 - 4 PM; Columbia Hall, Poster # 25160

MedImmune abstracts to be presented at NIC on influenza vaccines in specific populations and/or groups include:

  • A Post-Licensure Evaluation of the Safety of Live Attenuated Influenza Vaccine in Individuals 5 to 49 Years of Age. Toback, SL, et al. Poster Session: March 29, 2011 Time: 10 - 11 AM, 3 - 4 PM; Columbia Hall, Poster # 25173
  • A Postmarketing Evaluation of the Frequency of Use and Safety of Live Attenuated Influenza Vaccine in Non-Recommended Children Less Than 60 Months of Age. Toback, SL, et al. Poster Session: March 29, 2011 Time: 10 - 11 AM, 3 - 4 PM; Columbia Hall, Poster # 25166
  • Factors Associated with Increased In-Office Influenza Vaccine Coverage and Two-Dose Compliance Among U.S. Pediatricians. Toback, SL, et al. Poster Session: March 29, 2011 Time: 10 - 11 AM, 3 - 4 PM; Columbia Hall, Poster # 25177
  • Influenza Vaccination Attitudes and Beliefs Among U.S. Working Adults Attending Employer-Based Vaccination Clinics. Toback, SL, et al. Poster Session: March 29, 2011 Time: 10 - 11 AM, 3 - 4 PM; Columbia Hall, Poster # 25163
  • Maternal Outcomes in Pregnant Women Receiving Live Attenuated Influenza Vaccine. Toback, SL, et al. Poster Session: March 29, 2011 Time: 10 - 11 AM, 3 - 4 PM; Columbia Hall, Poster # 25172
  • Real-Time Assessment of the 2010-2011 Pediatric Influenza Vaccination Season. Toback SL, et al. Poster Session: March 29, 2011 Time: 10 - 11 AM, 3 - 4 PM; Columbia Hall, Poster # 25176
  • Trends in U.S. Pediatric Influenza Vaccination from 2006 to 2010. Toback, SL, et al. Poster Session: March 29, 2011 Time: 10 - 11 AM, 3 - 4 PM; Columbia Hall, Poster # 25161
  • U.S. Pediatric Influenza Vaccination by Pediatricians and Family Physicians From 2006 to 2010. Toback, SL, et al. Poster Session: March 29, 2011 Time: 10 - 11 AM, 3 - 4 PM; Columbia Hall, Poster # 25174

Additional information about the 2011 NIC conference can be found at http://www.cdc.gov/vaccines/events/nic/default.htm.

About MedImmune

MedImmune, the global biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,500 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising drug candidates, MedImmune strives to deliver life-changing products, a rewarding career to our employees and a tireless commitment to improving patient health. For more information, visit MedImmune's website at www.medimmune.com.


'/>"/>
SOURCE MedImmune
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MedImmune In-Licenses Clinical-Stage Anti-Inflammatory Monoclonal Antibody From Amgen
2. MedImmune Announces Winners of the 5th Annual Respiratory, Inflammation and Autoimmunity Research Abstract Competition
3. MedImmune Focused on Revolutionizing Cancer Care
4. MedImmune to Present Five Abstracts on RSV at Pediatric Academic Societies Annual Meeting
5. MedImmune to Present Data on RSV and Influenza at 2009 American Academy of Pediatrics National Conference & Exhibition
6. MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants
7. MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants
8. MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine
9. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
10. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
11. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 28, 2016  ValGenesis, Inc., the market ... (VLMS) today announced that a prominent world ... of chronic kidney failure has selected ValGenesis ... corporate validation process. The global medical device ... to manage their validation processes electronically. Upon ...
(Date:4/27/2016)... -- Hologic, Inc. (Nasdaq: HOLX ) announced ... second quarter ended March 26, 2016.  GAAP diluted ... and non-GAAP diluted EPS of $0.47 increased 14.6%.  ... reported basis, and 6.3% on a constant currency ... quarter, highlighted by 14.6% growth in non-GAAP EPS," ...
(Date:4/27/2016)... 2016   , ... Recurring Consumable Sales  Clinical sales grow 16% ... (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary ... the first quarter ended March 31, 2016 and provided ... its commercial strategy. First Quarter 2016 Revenue ...
Breaking Medicine Technology:
(Date:4/30/2016)... ... April 30, 2016 , ... Powerful tools ... Hypnotherapist, Mary O'Maley. What is hypnosis and hypnotherapy and why after centuries, ... control), pain relief (chronic and acute), birthing processes and medical procedures, depression, anxiety, ...
(Date:4/30/2016)... ... April 30, 2016 , ... ... and CEO of EMED, today signed a multifaceted agreement which will allow for ... Northern Caribbean University Department of Natural and Applied Sciences, Allied Health and Nursing ...
(Date:4/30/2016)... (PRWEB) , ... April 30, 2016 , ... Orlando-based Maximized ... as they go for gold in Rio. Under the care of Maximized Living ... golds! , In an unprecedented showing, Maximized Living is sending the largest contingent of ...
(Date:4/29/2016)... ... April 29, 2016 , ... In an article published April ... enthusiasm for Botox and lip injections, which she underwent in order to feel more ... Music and Arts Festival. The article explains that Ms. Mirmelli’s situation is not unique; ...
(Date:4/29/2016)... Arizona (PRWEB) , ... April 29, 2016 , ... ... Healing and Spiritual Awakening , announces the addition Onnit brand Alpha BRAIN and ... The addition of Onnit brain and mood optimization products to the store is ...
Breaking Medicine News(10 mins):